Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldosterone antagonist for diastolic dysfunction in hypertension with LV hypertrophy
ChiCTR-IPR-16009507Phase 4Recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in heart failure with preserved ejection fraction (HFpEF), hypertension (HTN) and left ventricular hypertrophy (LVH) comparing Spironolactone with Placebo (2 arms). Primary endpoint: Left ventricular diastolic function (E/E’ by tissue Doppler imaging). Started Oct 2016; status: recruiting.
02
Drugs
spironolactone
03
Conditions
heart failure with preserved ejection fraction (HFpEF)hypertension (HTN)left ventricular hypertrophy (LVH)
Beyond the preview
Go deeper on ChiCTR-IPR-16009507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16009507.